PDCD1 and non-small cell lung carcinoma: Durvalumab, an IgG1κ monoclonal antibody that blocks the interaction between PD‐L1 with PD‐1 and CD80,10 was recently approved for maintenance therapy following radical CRT in patients with unresectable Stage III NSCLC in the absence of disease progression after CRT.11, 12